Expression Pathology Inc. has announced a collaboration with The University of Texas MD Anderson Cancer Center to evaluate the use of the company’s tests for matching the most appropriate targeted therapies with lung cancer patients.
The research will study the company’s patented Liquid Tissue®-SRM technology, which enables accurate measurement of proteins in tumor pathways.
Lung cancer is the leading cause of cancer-related deaths worldwide. In the United States alone, there were an estimated 226,160 new cases and 160,340 deaths in 2012, with lung cancer accounting for 15% of cancer diagnoses but 28% of cancer deaths (American Cancer Society, Cancer Facts & Figures 2012).
A new generation of lung cancer drugs that target specific tumor pathways is having a significant positive impact on treatment, but improved testing methods are needed to help guide drug selection.
The advantage of Expression Pathology’s Liquid Tissue® SRM technology is the unique ability to quantify - in a single assay - multiple proteins involved in tumor pathways, in formalin-fixed paraffin-embedded (FFPE) tissue, the standard form of tissue preservation employed in medical practice worldwide.